MCID: APP010
MIFTS: 44

Appendix Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Appendix Cancer

MalaCards integrated aliases for Appendix Cancer:

Name: Appendix Cancer 12 15
Appendiceal Neoplasms 44 70
Malignant Neoplasm of Appendix Vermiformis 12
Malignant Tumor of the Appendix 12
Malignant Neoplasm of Appendix 70
Malignant Tumor of Appendix 12
Carcinoma of the Appendix 70
Cancer of the Appendix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11239
ICD9CM 34 153.5
MeSH 44 D001063
NCIt 50 C9333
SNOMED-CT 67 93679002
ICD10 32 C18.1
UMLS 70 C0003614 C0496779 C0728951

Summaries for Appendix Cancer

Disease Ontology : 12 A intestinal cancer that is located in the appendix.

MalaCards based summary : Appendix Cancer, also known as appendiceal neoplasms, is related to appendiceal neoplasm and appendix adenocarcinoma. An important gene associated with Appendix Cancer is KRT7 (Keratin 7), and among its related pathways/superpathways are Pathways in cancer and VEGF Signaling. The drugs Fentanyl and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include appendix, colon and lung, and related phenotypes are digestive/alimentary and neoplasm

Wikipedia : 73 Appendix cancer are very rare cancers of the vermiform... more...

Related Diseases for Appendix Cancer

Diseases related to Appendix Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 405)
# Related Disease Score Top Affiliating Genes
1 appendiceal neoplasm 31.3 SATB2 KRT7 KRAS HRAS GNAS CEACAM5
2 appendix adenocarcinoma 30.6 SMAD4 SATB2 KRT7 KRT20 KRAS HRAS
3 intestinal obstruction 29.9 KRT7 KRT20 CEACAM5 CDX2
4 pseudomyxoma peritonei 29.9 TP53 REG4 MUC6 MUC5AC MUC1 KRT7
5 krukenberg carcinoma 29.7 SATB2 KRT7 KRT20 CEACAM5 CDX2
6 neuroendocrine carcinoma 29.6 MUC1 KRT7 KRT20 CEACAM5
7 cystadenocarcinoma 29.0 TP53 MUC5AC MUC1 KRT7 HRAS CEACAM5
8 mucinous cystadenocarcinoma 28.9 SMAD4 MUC1 KRT7 KRT20 CEACAM5
9 mucinous adenocarcinoma 28.9 TP53 MUC5AC MUC1 KRT7 KRT20 KRAS
10 cystadenoma 28.7 REG4 MUC6 MUC5AC MUC1 KRT7 KRT20
11 adenocarcinoma 28.4 TP53 SMAD4 MUC1 KRT7 KRT20 KRAS
12 villous adenoma 28.0 TP53 MUC6 MUC5AC MUC1 KRT7 KRT20
13 ovarian cystadenocarcinoma 27.9 TP53 SMAD4 MUC6 MUC5AC MUC1 KRAS
14 adenoma 27.8 TP53 SMAD4 MUC6 MUC5AC MUC1 KRT7
15 signet ring cell adenocarcinoma 27.7 TP53 REG4 MUC6 MUC5AC MUC1 KRT7
16 appendix carcinoid tumor 11.0
17 ovary neuroendocrine neoplasm 10.4 KRT7 CDX2
18 anal canal paget's disease 10.4 KRT7 CDX2
19 gastric signet ring cell adenocarcinoma 10.4 KRT7 CDX2
20 adenosquamous colon carcinoma 10.4 KRT7 CDX2
21 bartholin's gland disease 10.4 KRT7 CDX2
22 leukoplakia of penis 10.4 KRT7 CEACAM5
23 bartholin's gland carcinoma 10.4 KRT7 CDX2
24 bladder benign neoplasm 10.4 KRT7 KRT20
25 rectum neuroendocrine neoplasm 10.4 KRT7 CDX2
26 malignant acrospiroma 10.4 KRT7 CEACAM5
27 laryngeal mucoepidermoid carcinoma 10.4 CEACAM5 CDX2
28 cutaneous mucoepidermoid carcinoma 10.4 KRT7 CEACAM5
29 external ear carcinoma 10.4 KRT7 CEACAM5
30 vulval paget's disease 10.4 KRT7 CEACAM5
31 eccrine adenocarcinoma 10.4 KRT7 CEACAM5
32 renal pelvis adenocarcinoma 10.4 KRT7 CEACAM5
33 papillary squamous carcinoma 10.4 KRT7 CEACAM5
34 adenoid basal cell carcinoma 10.4 KRT7 CEACAM5
35 nephrogenic adenoma of urinary bladder 10.4 KRT7 KRT20
36 atrophic vulva 10.4 KRT7 KRT20
37 pancreatic cystadenocarcinoma 10.4 KRAS CEACAM5
38 ethmoid sinus cancer 10.4 HRAS CDX2
39 pericardium cancer 10.4 KRT7 CEACAM5
40 urinary bladder small cell neuroendocrine carcinoma 10.4 KRT7 KRT20
41 eyelid carcinoma 10.4 KRT7 KRT20
42 clear cell hidradenoma 10.4 KRT7 CEACAM5
43 hidrocystoma 10.4 KRT7 CEACAM5
44 liver sarcoma 10.3 KRT7 CEACAM5
45 ovarian large-cell neuroendocrine carcinoma 10.3 KRT7 KRT20
46 supine hypotensive syndrome 10.3 KRT7 KRT20
47 mucinous stomach adenocarcinoma 10.3 KRT7 CDX2
48 cervical mucinous adenocarcinoma 10.3 MUC6 KRT7
49 meibomian cyst 10.3 KRT7 KRT20
50 hepatic flexure cancer 10.3 KRAS HRAS

Comorbidity relations with Appendix Cancer via Phenotypic Disease Network (PDN):


Cecal Benign Neoplasm

Graphical network of the top 20 diseases related to Appendix Cancer:



Diseases related to Appendix Cancer

Symptoms & Phenotypes for Appendix Cancer

MGI Mouse Phenotypes related to Appendix Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.5 CDX2 HRAS KRAS MUC5AC SATB2 SMAD4
2 neoplasm MP:0002006 9.1 CDX2 GNAS HRAS KRAS SMAD4 TP53

Drugs & Therapeutics for Appendix Cancer

Drugs for Appendix Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
3
Ondansetron Approved Phase 3 99614-02-5 4595
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
5 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
6 Hormones Phase 3
7 Narcotics Phase 3
8 Anesthetics Phase 3
9 Anesthetics, Intravenous Phase 3
10 Anesthetics, General Phase 3
11 Analgesics, Opioid Phase 3
12 Analgesics Phase 3
13 Antiemetics Phase 3
14 Neurotransmitter Agents Phase 3
15 Psychotropic Drugs Phase 3
16 glucocorticoids Phase 3
17 Hormone Antagonists Phase 3
18 Antineoplastic Agents, Hormonal Phase 3
19 Anti-Inflammatory Agents Phase 3
20 Antipsychotic Agents Phase 3
21 Anti-Anxiety Agents Phase 3
22 Dermatologic Agents Phase 3
23
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
24
Fluorouracil Approved Phase 2 51-21-8 3385
25
Pancrelipase Approved, Investigational Phase 2 53608-75-6
26
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
27
leucovorin Approved Phase 2 58-05-9 6006
28
Melphalan Approved Phase 2 148-82-3 4053 460612
29
Floxuridine Approved Phase 2 50-91-9 5790
30
Ipilimumab Approved Phase 2 477202-00-9
31
nivolumab Approved Phase 2 946414-94-4
32
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
33
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
34
Dexlansoprazole Approved, Investigational Phase 2 138530-94-6, 103577-45-3 9578005
35
Clarithromycin Approved Phase 2 81103-11-9 84029
36
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613
37
Lansoprazole Approved, Investigational Phase 2 103577-45-3 3883
38
carbamide peroxide Approved Phase 2 124-43-6
39
Palonosetron Approved, Investigational Phase 2 135729-56-5, 119904-90-4 148211
40
Nintedanib Approved Phase 2 656247-17-5 56843413
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
42 pancreatin Phase 2
43 Angiogenesis Inhibitors Phase 2
44 Antidotes Phase 2
45 Trace Elements Phase 2
46 Micronutrients Phase 2
47 Vitamin B9 Phase 2
48 Nutrients Phase 2
49 Cola Phase 2
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
4 Randomized Therapeutic Study Comparing Tumor Resection Followed Immediately by Intraperitoneal Chemotherapy and Systemic Chemotherapy VS Systemic Chemotherapy Alone for the Treatment of Colorectal Cancer Metastatic to the Peritoneum Unknown status NCT00006112 Phase 2 chemotherapy;fluorouracil;leucovorin calcium;mitomycin C
5 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
6 Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer Completed NCT00310076 Phase 2 thalidomide
7 A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After HIPEC With Oxaliplatin or Mitomycin C in Patients With Appendiceal Tumors Completed NCT01580410 Phase 2 mitomycin C;oxaliplatin;hyperthermic intraperitoneal chemotherapy
8 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Completed NCT02040142 Phase 2 Mitomycin C
9 Repetitive Electrostatic Pressurised Intraperitoneal Aerosol Chemotherapy With Oxaliplatin (ePIPAC-OX) as a Palliative Monotherapy for Isolated Unresectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Single-arm, Phase II Study (CRC-PIPAC) Completed NCT03246321 Phase 2
10 ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis Recruiting NCT01815359 Phase 2 HIPEC with Mitomycin-C;EPIC with FUDR and Leucovorin
11 A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors Recruiting NCT03693846 Phase 2 Nivolumab;Ipilimumab
12 A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting NCT02963831 Phase 1, Phase 2 Durvalumab
13 Phase II Single-Blind Randomized Trial Comparing Morbidity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis Recruiting NCT03073694 Phase 2 Mitomycin c;Melphalan
14 Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy Active, not recruiting NCT02387203 Phase 2 PrevPac (Prevacid, Amoxicillin, Clarithromycin)
15 A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting Terminated NCT00903396 Phase 2 palonosetron hydrochloride
16 LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma Terminated NCT03287947 Phase 2 nintedanib
17 A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 A Phase I Evaluation of Intraperitoneal Hyperthermic Chemoperfusion With Oxaliplatin for Peritoneal Surface Disemmination of Appendiceal and Colorectal Cancer Completed NCT00458809 Phase 1 oxaliplatin
19 Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
20 A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity Completed NCT00055705 Phase 1
21 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
22 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
23 Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
24 Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
25 Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas Completed NCT00003046 Phase 1
26 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
27 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat
28 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
29 Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous mFOLFIRI for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer Recruiting NCT04158349 Phase 1 Oxaliplatin;mFOLFIRI
30 Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer Recruiting NCT02833753 Phase 1 Oxaliplatin
31 Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) Recruiting NCT04329494 Phase 1 Cisplatin;Doxorubicin;Fluorouracil;Leucovorin;Oxaliplatin
32 Improving Palliative Care for Patients With Cancer Completed NCT00253383
33 GI 1549: PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A Randomized Controlled Pilot Study of Yoga Compared to an Attention Control in Patients Receiving Chemotherapy Completed NCT02489422
34 A Survey of the Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients Completed NCT02374411
35 Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins Recruiting NCT03604653 Mitomycin c;CDDP 50;CDDP 75;Doxorubicin
36 5-hydroxymethylation Signatures in Plasma Circulating Cell-free DNA as Markers for Tumor Burden and Recurrence in Appendiceal and Colorectal Peritoneal Metastasis Recruiting NCT04157322
37 A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread Recruiting NCT02599116
38 A Pragmatic, Single-Arm Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy Recruiting NCT04526886
39 Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases Recruiting NCT03210298
40 Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy; the FANCY Study. Active, not recruiting NCT03510923
41 The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Not yet recruiting NCT04028479 Systemic Treatment (T)
42 Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix: An International Multicenter Study Not yet recruiting NCT03852693
43 The Prevalence of Appendiceal Tumours in Patients Presenting With a Periappendicular Abscess - A Nationwide Prospective Cohort Study Not yet recruiting NCT04634448

Search NIH Clinical Center for Appendix Cancer

Cochrane evidence based reviews: appendiceal neoplasms

Genetic Tests for Appendix Cancer

Anatomical Context for Appendix Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Appendix Cancer:

19
Appendix

MalaCards organs/tissues related to Appendix Cancer:

40
Appendix, Colon, Lung, Ovary, Liver, Breast, Thyroid

Publications for Appendix Cancer

Articles related to Appendix Cancer:

(show top 50) (show all 213)
# Title Authors PMID Year
1
Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix. 61 54
7545815 1995
2
Acute appendiceal diverticulitis: a case report. 61
33717385 2021
3
PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. 61
33148667 2021
4
Quality analysis of operative reports and referral data for appendiceal neoplasms with peritoneal dissemination. 61
33190916 2021
5
Do the 'Eyes' have it? How good are surgeons at identifying appendicitis macroscopically? A retrospective study in NewZealand. 61
33767487 2021
6
Molecular and clinicopathological features of appendiceal mucinous neoplasms. 61
32821969 2021
7
Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix? 61
33360118 2021
8
Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer. 61
33164812 2021
9
A case report of incarcerated inguinal hernia: Amyand's hernia with adenocarcinoma tumor. 61
33714896 2021
10
Current Management of Appendiceal Neoplasms. 61
33770459 2021
11
Mucinous appendiceal neoplasm: A case report. 61
33728318 2021
12
Clinicopathological Characteristics of Low-Grade Appendiceal Mucinous Neoplasm. 61
33691316 2021
13
A Low-Grade Appendiceal Mucinous Neoplasia and Neuroendocrine Appendiceal Collision Tumor: A Case Report and Review of the Literature. 61
33619239 2021
14
Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. 61
33022181 2021
15
A retrospective analysis and literature review of neoplastic appendiceal mucinous lesions. 61
33573654 2021
16
Risk of appendiceal neoplasm after interval appendectomy for complicated appendicitis: A systematic review and meta-analysis. 61
33640282 2021
17
Immunohistochemistry features and molecular pathology of appendiceal neoplasms. 61
33569997 2021
18
Rising incidence of appendiceal neoplasms over time: Does pathological handling of appendectomy specimens play a role? 61
33667971 2021
19
The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. 61
32808135 2021
20
Primary appendiceal Burkitt's lymphoma presenting as acute appendicitis: An extremely rare case report and review of the literatture. 61
33363721 2021
21
Leiomyosarcoma mimicking acute appendicitis: a cautionary tale! 61
33495185 2021
22
Impact of signet ring cells on overall survival in peritoneal disseminated appendix cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 61
33272738 2021
23
Preoperative Factors Associated with Appendiceal Tumors in Nonelective Appendectomy. 61
32678991 2020
24
Implications of the presence of the vermiform appendix inside an inguinal hernia (Amyand's hernia): a systematic review of the literature. 61
32451789 2020
25
Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. 61
32761790 2020
26
Laparoscopic hyperthermic intraperitoneal chemotherapy for appendiceal tumors. 61
31997552 2020
27
Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors. 61
32869188 2020
28
Appendiceal neoplasms and histological involvement of the mesoappendix: A case series. 61
32577233 2020
29
Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). 61
33280949 2020
30
Interval laparoscopic appendectomy after antibiotic therapy for appendiceal abscess in elderly patients. 61
31621202 2020
31
Is interval appendectomy really needed? A closer look at neoplasm rates in adult patients undergoing interval appendectomy after complicated appendicitis. 61
32676725 2020
32
Impact of Referral Center Pathology Review on Diagnosis and Management of Patients With Appendiceal Neoplasms. 61
31714810 2020
33
Repeat cytoreductive surgery with or without intraperitoneal chemotherapy for recurrent epithelial appendiceal neoplasms. 61
32020757 2020
34
The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. 61
32282073 2020
35
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. 61
32285275 2020
36
[Retrospective investigation of patients receiving additional surgery after endoscopic non-curative resection for early colorectal cancer]. 61
32842429 2020
37
Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. 61
31720933 2020
38
Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors. 61
31958897 2020
39
SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. 61
31595536 2020
40
Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection. 61
31368017 2020
41
Mucinous appendiceal adenocarcinomas: a diagnostic challenge. 61
31988709 2020
42
Synchronous primary neuroendocrine and mucinous epithelial tumors present in the same appendix. Case report of 2 patients. 61
32035310 2020
43
Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. 61
31602579 2020
44
Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei. 61
31541325 2019
45
[Appendix Cancer with Long-Term Survival after Multimodality Therapy-A Case Report]. 61
32156998 2019
46
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. 61
31239549 2019
47
The American Society of Colon and Rectal Surgeons, Clinical Practice Guidelines for the Management of Appendiceal Neoplasms. 61
31725580 2019
48
Intraoperative packed red blood cell transfusion (iPRBT) and PCI-normalised iPRBT rates (iPRBT/PCI ratio) negatively affect short- and long-term outcomes of patients undergoing cytoreductive surgery and intraperitoneal chemotherapy - An analysis of 880 patients. 61
31444027 2019
49
Correlation of molecular and morphological features of appendiceal epithelial neoplasms. 61
31111538 2019
50
Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. 61
30685879 2019

Variations for Appendix Cancer

Expression for Appendix Cancer

Search GEO for disease gene expression data for Appendix Cancer.

Pathways for Appendix Cancer

Pathways related to Appendix Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1 12.69 TP53 SMAD4 KRAS HRAS GNAS
2
Show member pathways
12.16 TP53 MUC1 KRAS HRAS
3 12.14 TP53 SMAD4 KRAS HRAS
4
Show member pathways
12.1 TP53 SMAD4 REG4 KRAS HRAS CDX2
5
Show member pathways
12.02 MUC6 MUC5B MUC5AC MUC1
6 11.95 TP53 SMAD4 KRAS GNAS
7 11.89 TP53 KRAS HRAS
8 11.87 TP53 KRAS HRAS
9
Show member pathways
11.87 MUC6 MUC5B MUC5AC MUC1
10 11.85 KRAS HRAS GNAS
11 11.83 TP53 KRAS HRAS
12
Show member pathways
11.82 KRAS HRAS GNAS
13 11.81 KRT20 KRAS HRAS GNAS
14 11.8 TP53 SMAD4 HRAS
15 11.77 SMAD4 KRAS HRAS
16 11.7 KRAS HRAS GNAS
17 11.62 TP53 SMAD4 KRAS HRAS
18 11.6 TP53 KRAS HRAS
19 11.57 SMAD4 KRAS HRAS
20 11.56 TP53 KRAS HRAS
21 11.53 TP53 KRAS HRAS
22
Show member pathways
11.51 MUC6 MUC5B MUC5AC MUC1 KRAS HRAS
23
Show member pathways
11.49 MUC6 MUC5B MUC5AC MUC1
24 11.43 KRAS HRAS GNAS
25 10.97 SMAD4 KRAS HRAS
26 10.7 KRAS HRAS

GO Terms for Appendix Cancer

Cellular components related to Appendix Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 REG4 PRSS36 MUC6 MUC5B MUC5AC MUC1
2 Golgi lumen GO:0005796 8.92 MUC6 MUC5B MUC5AC MUC1

Biological processes related to Appendix Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.5 TP53 KRAS HRAS
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 TP53 MUC1
3 response to isolation stress GO:0035900 9.26 KRAS HRAS
4 O-glycan processing GO:0016266 9.26 MUC6 MUC5B MUC5AC MUC1
5 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.16 TP53 MUC1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.1 MUC6 MUC5B MUC5AC MUC1 KRAS HRAS

Sources for Appendix Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....